Drug Trial Radar · NCT06609005
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Jan 23, 2025
Primary completion
Jan 17, 2028
Study completion Jan 17, 2028
Sponsor
- Lead sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Conditions
- Advanced Metastatic Castration Resistant Prostate Cancer
Interventions
INV-9956Drug
INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Maximum tolerated dose (MTD)Time frame: Within first 28 days of treatment
- Phase 1: Recommended dose range (RDR)Time frame: 12 months
- Phase 2: Evaluate Radiographic progression-free survival (rPFS)Time frame: 12 months
- Phase 2: Evaluate overall response rate (ORR)Time frame: 12 months
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Honor Health
Scottsdale, Arizona · Recruiting
Hoag Family Cancer Institute
Newport Beach, California · Recruiting
UC Irvine Medical Center
Orange, California · Recruiting
Next Oncology - Houston
Houston, Texas · Recruiting
UT Health
San Antonio, Texas · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Summit Cancer Centers
Spokane, Washington · Recruiting
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
The First People's Hospital of Foshan
Foshan, Guangdong, China · Not yet recruiting
He'nan Cancer Hospital
Zhengzhou, He'Nan, China · Recruiting
Hu'nan Cancer Hospital
Changsha, Hu'Nan, China · Not yet recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
Shandong Cancer Hospital
Ji'nan, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hubei, Wuhan, China · Not yet recruiting
The First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.